Zydus Lifesciences quarterly results and financials

Zydus Lifesciences (ZYDUSLIFE)₹1,216+1.37%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Zydus Lifesciences reported sales of ₹8,034 Cr, up 21.8% from Jun 2025, and net profit of ₹991 Cr, down 35.0% year on year. For the year to Mar 2026, sales were ₹27,233 Cr and net profit ₹5,129 Cr.

Sales (Jun 2026): ₹8,034 Cr
Net profit (Jun 2026): ₹991 Cr
Sales (FY Mar 2026): ₹27,233 Cr
Net profit (FY Mar 2026): ₹5,129 Cr
EPS (Jun 2026): ₹9.43
Borrowings (Mar 2026): ₹12,493 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Zydus Lifesciences quarterly results

₹ crore unless stated; each column is a quarter.

Zydus Lifesciences Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	4,379	4,520	5,550	6,227	5,253	5,283	6,542	6,596	6,139	6,884	7,611	8,034
Expenses	3,230	3,414	3,915	4,137	3,783	3,891	4,416	4,499	4,115	5,058	5,045	6,103
Operating Profit	1,150	1,106	1,635	2,094	1,467	1,393	2,136	2,096	2,025	1,823	2,566	1,936
OPM %	26.1%	24.0%	29.0%	34.1%	28.0%	26.0%	33.1%	32.0%	33.0%	26.1%	34.0%	24.0%
Other Income	53.12	60.10	160	63.11	68.15	57.11	−139	155	75.18	26.06	−263	88.18
Interest	8.99	19.97	34.97	31.95	24.96	31.99	76.91	84.91	101	130	123	156
Depreciation	185	196	206	216	235	230	239	239	303	361	510	557
Profit before tax	1,003	945	1,545	1,896	1,267	1,181	1,668	1,915	1,682	1,349	1,656	1,305
Tax %	22.0%	23.0%	21.0%	23.0%	29.0%	15.0%	25.0%	23.0%	27.0%	29.0%	19.0%	27.0%
Exceptional items	−0.99	21.94	2.99	0.00	0.00	0.00	−88.72	0.00	−24.91	−60.83	−271	−12.96
Net Profit	804	791	1,249	1,485	922	1,027	1,247	1,524	1,241	1,026	1,342	991
EPS (Rs)	7.92	7.81	11.77	14.14	9.08	10.19	11.66	14.61	12.52	10.38	12.68	9.43

Zydus Lifesciences profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Zydus Lifesciences Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	9,452	9,409	11,931	13,211	14,294	15,133	15,316	17,284	19,603	23,291	27,233	28,667
Expenses	7,110	7,496	9,094	10,203	11,477	11,796	11,957	13,413	14,206	16,233	18,718	20,321
Operating Profit	2,342	1,909	2,844	3,005	2,811	3,357	3,357	3,872	5,402	7,090	8,515	8,349
OPM %	25.1%	20.0%	24.0%	23.0%	20.1%	22.0%	22.0%	22.1%	28.0%	30.1%	31.0%	29.1%
Other Income	112	127	111	183	−264	−171	2,584	−422	294	50.11	−7.01	−74.04
Interest	52.97	44.97	90.89	194	342	164	127	130	80.92	166	439	510
Depreciation	293	374	541	601	698	727	715	726	766	920	1,414	1,731
Profit before tax	2,093	1,608	2,307	2,374	1,492	2,278	5,073	2,579	4,816	6,013	6,605	5,991
Tax %	8.0%	8.0%	24.0%	22.0%	21.0%	6.0%	10.0%	23.0%	20.0%	23.0%	24.0%	—
Exceptional items	−2.99	−0.99	31.90	55.79	−259	−165	122	−427	−0.99	−124	−391	−370
Net Profit	1,966	1,521	1,813	1,903	1,207	2,190	4,628	2,095	3,982	4,685	5,129	4,601
EPS (Rs)	18.93	14.55	17.38	18.09	11.52	20.89	43.92	19.41	38.43	45.06	50.21	45.01
Dividend payout %	17.1%	22.1%	20.1%	19.1%	30.1%	17.1%	6.1%	31.1%	8.0%	24.1%	2.0%	—

Zydus Lifesciences balance sheet

₹ crore, at each year end.

Zydus Lifesciences Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	102	102	102	102	102	102	102	102	101	101	101	101
Reserves	4,161	5,614	6,877	8,663	10,303	10,293	12,912	16,935	17,467	19,787	23,916	27,074
Borrowings	2,654	2,445	5,210	5,406	7,900	7,986	4,587	4,224	1,196	805	3,215	12,493
Other Liabilities	2,139	2,198	2,923	3,615	4,921	5,090	6,159	6,390	6,818	8,162	9,477	11,012
Total Liabilities	9,057	10,360	15,112	17,786	23,227	23,472	23,760	27,652	25,582	28,854	36,710	50,680
Fixed Assets	3,349	3,742	5,743	6,468	12,135	12,210	12,109	12,237	11,508	12,355	13,121	24,062
CWIP	801	955	1,549	1,532	840	744	785	663	1,205	2,433	2,701	3,707
Investments	154	417	436	748	676	767	832	3,294	1,551	1,223	6,424	7,552
Other Assets	4,753	5,247	7,384	9,039	9,576	9,751	10,034	11,456	11,319	12,842	14,464	15,358
Inventories	1,538	1,338	1,805	2,387	2,692	2,792	3,239	3,721	3,418	3,447	3,949	5,628
Trade receivables	1,594	1,754	2,289	3,217	3,970	3,680	3,141	3,354	4,436	5,239	4,099	5,441
Cash & equivalents	670	639	1,545	1,315	549	966	889	1,107	573	1,105	2,959	1,417
Total Assets	9,057	10,360	15,112	17,786	23,227	23,472	23,760	27,652	25,582	28,854	36,710	50,680

Zydus Lifesciences cash flow

₹ crore, for each year.

Zydus Lifesciences Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	993	1,892	1,311	918	1,281	2,502	3,286	2,100	2,684	3,224	6,775	2,115
Cash from investing activity	−465	−859	−2,871	−973	−3,972	−1,010	−835	1,135	1,177	−1,491	−8,352	−7,891
Cash from financing activity	−352	−938	2,325	52.21	1,892	−1,099	−2,560	−872	−4,416	−1,816	2,003	5,827
Net cash flow	178	99.10	757	−3.01	−812	400	−90.11	2,376	−534	−75.09	415	28.01
Capex	512	961	2,939	1,048	1,056	903	854	1,202	1,030	906	1,693	2,670
Free cash flow	500	938	−1,628	−116	237	1,621	2,453	1,053	1,703	2,353	5,157	−531
CFO / OP %	79.1%	109.1%	81.1%	54.0%	65.0%	100.0%	109.1%	83.0%	85.1%	84.1%	122.0%	44.1%

Zydus Lifesciences ratios

Working-capital days and returns, by year.

Zydus Lifesciences Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	67	68	89	98	110	94	76	80	94	97	64	73
Inventory days	174	157	192	210	207	206	226	244	196	201	226	281
Days payable	125	154	165	167	149	151	155	141	123	125	131	142
Cash conversion cycle	118	71	116	142	169	150	148	184	168	175	160	212
Working capital days	7	0	−33	18	11	−18	−5	20	71	89	4	−39
ROCE %	23.1%	28.1%	16.1%	18.1%	15.1%	11.1%	14.1%	13.1%	15.1%	22.1%	24.1%	21.1%

Zydus Lifesciences: frequently asked questions

What are the latest quarterly results of Zydus Lifesciences?

For the Jun 2026 quarter, Zydus Lifesciences reported sales of ₹8,034 Cr, up 21.8% year on year and net profit of ₹991 Cr, down 35.0% year on year. The operating margin was 24.0%.

What is the annual revenue of Zydus Lifesciences?

Zydus Lifesciences' sales for the year to Mar 2026 were ₹27,233 Cr; over the last twelve months they were ₹28,667 Cr.

What is the net profit of Zydus Lifesciences?

Net profit for the year to Mar 2026 was ₹5,129 Cr, and ₹4,601 Cr over the last twelve months. Earnings per share over the same trailing period were ₹45.01.

How much debt does Zydus Lifesciences have?

Zydus Lifesciences reported borrowings of ₹12,493 Cr at Mar 2026, against cash and equivalents of ₹1,417 Cr.

What is the free cash flow of Zydus Lifesciences?

Cash from operations was ₹2,115 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹531 Cr.

Loading…